- Home
- URGN vs PNTG Comparison
URGN vs PNTG Comparison
Compare URGN & PNTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- PNTG
- Stock Information
- Founded
- URGN 2004
- PNTG 2019
- Country
- URGN United States
- PNTG United States
- Employees
- URGN N/A
- PNTG N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- PNTG Medical/Nursing Services
- Sector
- URGN Health Care
- PNTG Health Care
- Exchange
- URGN Nasdaq
- PNTG Nasdaq
- Market Cap
- URGN 830.4M
- PNTG 841.6M
- IPO Year
- URGN 2017
- PNTG N/A
- Fundamental
- Price
- URGN $20.62
- PNTG $25.05
- Analyst Decision
- URGN Strong Buy
- PNTG Buy
- Analyst Count
- URGN 8
- PNTG 6
- Target Price
- URGN $28.50
- PNTG $33.67
- AVG Volume (30 Days)
- URGN 921.6K
- PNTG 277.2K
- Earning Date
- URGN 11-06-2025
- PNTG 11-05-2025
- Dividend Yield
- URGN N/A
- PNTG N/A
- EPS Growth
- URGN N/A
- PNTG 20.56
- EPS
- URGN N/A
- PNTG 0.77
- Revenue
- URGN $94,238,000.00
- PNTG $798,923,000.00
- Revenue This Year
- URGN $36.41
- PNTG $29.63
- Revenue Next Year
- URGN $118.04
- PNTG $14.84
- P/E Ratio
- URGN N/A
- PNTG $32.49
- Revenue Growth
- URGN 10.85
- PNTG 30.58
- 52 Week Low
- URGN $3.42
- PNTG $21.18
- 52 Week High
- URGN $21.71
- PNTG $34.36
- Technical
- Relative Strength Index (RSI)
- URGN 63.69
- PNTG 52.77
- Support Level
- URGN $19.17
- PNTG $24.26
- Resistance Level
- URGN $21.00
- PNTG $26.13
- Average True Range (ATR)
- URGN 1.12
- PNTG 0.75
- MACD
- URGN 0.35
- PNTG 0.05
- Stochastic Oscillator
- URGN 83.19
- PNTG 62.11
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About PNTG The Pennant Group Inc.
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.